🖼
Figure 2 — Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyel
active
paper figure
Created: 2026-04-21T18:29:40
By: paper_figures_tool
Quality:
50%
🔗 External
ID: paper-fig-paper-40988129-2
Figure 2Figure 2
CSF levels of MMP-9, tissue damage markers and complement factors in acute myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS) and symptomatic controls (SC) . Box plots showing CSF concentrations of matrix metalloproteinase-9 (MMP-9; A ), neurofilament light chain (NfL; B ), glial fibrillary acidic protein (GFAP; C ), S100 calcium-binding protein B (S100B; D ), complement factor C5 ( E ) and complement activation product C5a ( F ) across patient groups. Data are presented on a double logarithmic scale ( y -axis; concentrations in pg/ml, except for C5 in ng/ml). Statistical comparisons were performed using the Wilcoxon rank-sum test; significance thresholds are denoted as: ns (not significant), P > 0.05; * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.
▸Metadata
| pmid | paper-40988129 |
| caption | CSF levels of MMP-9, tissue damage markers and complement factors in acute myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), mult |
| image_url | https://www.ebi.ac.uk/europepmc/articles/PMC13058455/bin/awaf345f2.jpg |
| paper_title | Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis. |
| figure_label | Figure 2 |
| figure_number | 2 |
| _schema_version | 1 |
| source_strategy | pmc_api |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.